Inhaled Nitric Oxide Delivery Systems Market Worth $434.2 Million By 2028

Inhaled Nitric Oxide Delivery Systems Market Growth & Trends

The global inhaled nitric oxide delivery systems market size is estimated to reach USD 434.2 million by 2028 registering a CAGR of 6.9%, according to a new report by Grand View Research, Inc. A rise in the cases of respiratory failure among neonates, increased pollution levels leading to lung diseases in adults, need for quick treatment response, and reduced complications are the factors driving the adoption of inhaled nitric oxide therapy. The presence of several small-scale manufacturers and research initiatives undertaken by major players to prove treatment efficacy against the SARS-CoV-2 virus further enhances market growth.

Safe and effective treatment regimen, a rapid offset of action, reduced toxicity, high concentration of drug at the target organ, avoidance of systemic adverse reaction, and reduced dose of medication are some of the advantages of INO over other medications. This leads to the improved adoption of INO, potentially driving the market growth. Market leaders like Mallinckrodt Pharmaceuticals are providing fundings to conduct clinical trials of INO therapy to treat complications in COVID-19 patients. Such initiatives are said to boost the market growth during the forecasted period.

 Request a free sample copy or view report summary: Inhaled Nitric Oxide Delivery Systems Market Report

 Inhaled Nitric Oxide Delivery Systems Market Report Highlights

• The pediatric type segment accounted for the largest revenue share in 2020 due to the rising usage of INO therapy on account of its efficacy and reduced complications

• The Hypoxic Respiratory Failure (HRF) application segment held the largest revenue share in 2020

• Hospitals was the largest revenue-generating segment in 2020 owing to the presence of funds and well-established infrastructure in this end-user setting

• Asia Pacific was the largest regional market in 2020 due to the growing pediatric population, rise in the cases of respiratory diseases, and presence of local manufacturers of disposables

• Some of the prominent companies are Mallinckrodt Pharmaceuticals, Getinge, Vero Biotech, LINDE, Beyond Air, SLE, Nu-MED, Bellerophon Therapeutics, Air Liquide Healthcare, and Circassia Pharmaceuticals

Inhaled Nitric Oxide Delivery Systems Market Segmentation

Grand View Research has segmented the global inhaled nitric oxide delivery systems market on the basis of type, product, application, end user, and region:

INO Delivery Systems Type Outlook (Revenue, USD Million, 2016 - 2028)

• Pediatrics

• Adult

INO Delivery Systems Application Outlook (Revenue, USD Million, 2016 - 2028)

• Hypoxic Respiratory Failure (HRF)

• Acute Hypoxemic Respiratory Failure (AHRF)

• Others

INO Delivery Systems Product Outlook (Revenue, USD Million, 2016 - 2028)

• Disposables

• System

INO Delivery Systems End-user Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals

• Ambulatory Centers

• Clinics

INO Delivery Systems Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Sweden

  • Russia

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Turkey

List of Key Players of Inhaled Nitric Oxide Delivery Systems Market

• Mallinckrodt Pharmaceuticals

• Getinge

• Vero Biotech

• LINDE

• Beyond Air

• SLE

• NU MED

• Bellerophon Therapeutics

• Air Liquide Healthcare

• Circassia Pharmaceuticals